| Stage | HCA | % of rev | SGRY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $19.8B | 100.00% | $849M | 100.00% | HCA ×23.38 |
| Gross profit | $11.3B | 56.77% | $596M | 70.18% | SGRY +13.4pp |
| Operating income | $3.0B | 14.90% | $102M | 12.03% | HCA +2.9pp |
| Pre-tax income | $2.4B | 11.94% | $32M | 3.80% | HCA +8.1pp |
| Net income | $1.8B | 9.32% | $30M | 3.50% | HCA +5.8pp |
| Stage | HCA | SGRY | Gap · A − B |
|---|---|---|---|
| Revenue | $19.8B100.00% | $849M100.00% | HCA ×23.38 |
| Gross profit | 56.77%$11.3B | 70.18%$596M | SGRY +13.4pp |
| Operating income | 14.90%$3.0B | 12.03%$102M | HCA +2.9pp |
| Pre-tax income | 11.94%$2.4B | 3.80%$32M | HCA +8.1pp |
| Net income |
| 9.32%$1.8B |
| 3.50%$30M |
| HCA +5.8pp |
No shared counterparties.